Literature DB >> 30509750

National variation in opioid prescribing after pediatric umbilical hernia repair.

Randi S Cartmill1, Dou-Yan Yang2, Sara Fernandes-Taylor2, Jonathan Emerson Kohler2.   

Abstract

BACKGROUND: Pediatric umbilical hernia repair is a common procedure that requires minimal tissue disruption. We examined variation in opioid prescription fills after repair of uncomplicated umbilical hernias to characterize the types and doses of medication used and persistent postsurgical use.
METHODS: Using the Truven Health Analytics MarketScan© Research Database for June 2012-September 2015, we identified pediatric patients undergoing umbilical hernia repair. We excluded patients with obstruction, gangrene, an earlier repair or a concurrent surgical procedure, and those without available pharmacy claim data. Analyses describe filled outpatient prescriptions by age, geographic region, drug type, quantity, and second prescriptions/refills.
RESULTS: Of 4,407 procedures performed, 2,292 patients (52%) filled a prescription for postoperative opioids (age 0-1 years: 21.6%, age 2-3 years: 51.5%, age 4-5 years: 54.3%, 6 years or older: 57.9% [P < .0001]). In the northeast United States, 42% of patients filled narcotic prescriptions, compared with 59% of patients in the south (P < .0001). Hydrocodone/acetaminophen was most commonly prescribed (51%), followed by codeine/acetaminophen (30%). Durations were ≤3 days (50%), 4-10 days (46%), and >10 days (4%). A total of 6% of patients filled a second opioid prescription within 30 days.
CONCLUSION: Although many patients do not require opioids for umbilical hernia repair, most pediatric patients fill opioid prescriptions, including for prolonged courses and refills. Guidelines for appropriate prescribing of opioids after common, simple procedures, such as umbilical hernia repair, could improve the quality of care for children and impact the US epidemic of opioid abuse.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30509750     DOI: 10.1016/j.surg.2018.10.029

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Perioperative Opioid Exposure Patterns in Pediatric Anterior Cruciate Ligament Reconstruction: A Ten-Year Administrative Database Study.

Authors:  Dharman Anandarajan; Brendan A Williams; Nathan D Markiewitz; Divya Talwar; Lawrence Wells
Journal:  Cureus       Date:  2021-03-16

2.  Impact of prescription drug monitoring program mandate on postoperative opioid prescriptions in children.

Authors:  Christina M Theodorou; Jordan E Jackson; Ganesh Rajasekar; Miriam Nuño; Kaeli J Yamashiro; Diana L Farmer; Shinjiro Hirose; Erin G Brown
Journal:  Pediatr Surg Int       Date:  2021-01-12       Impact factor: 1.827

3.  Variability in opioid pain medication prescribing for adolescent trauma patients in a sample of US pediatric trauma centers.

Authors:  Michael J Mello; Janette Baird; Julie R Bromberg; Anthony Spirito; Mark R Zonfrillo; Lois K Lee; Emily R Christison-Lagay; Stephanie M Ruest; Charles W Pruitt; Karla A Lawson; Andrew W Kiragu; Isam Nasr; Jeremy T Aidlen; Beth E Ebel; R Todd Maxson; Kelli Scott; Sara J Becker
Journal:  Trauma Surg Acute Care Open       Date:  2022-04-26

4.  Evaluating Opioid Dispensing Rates among Pediatrics and Young Adults based on CURES Data Reporting in California from 2015-2019.

Authors:  Michael T Phan; Courtney Wong; Daniel M Tomaszewski; Zeev N Kain; Brooke Jenkins; Candice Donaldson; Michelle Fortier; Sun Yang
Journal:  J Contemp Pharm Prac       Date:  2021-03-03

Review 5.  Guidelines for Opioid Prescribing in Children and Adolescents After Surgery: An Expert Panel Opinion.

Authors:  Lorraine I Kelley-Quon; Matthew G Kirkpatrick; Robert L Ricca; Robert Baird; Calista M Harbaugh; Ashley Brady; Paula Garrett; Hale Wills; Jonathan Argo; Karen A Diefenbach; Marion C W Henry; Juan E Sola; Elaa M Mahdi; Adam B Goldin; Shawn D St Peter; Cynthia D Downard; Kenneth S Azarow; Tracy Shields; Eugene Kim
Journal:  JAMA Surg       Date:  2021-01-01       Impact factor: 14.766

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.